| SC 13G/A | 2024-04-05 | BlackRock Inc. | Kiniksa Pharmaceuticals, Ltd. | 4,192,446 | 10.5% | EDGAR |
| SC 13G/A | 2024-02-14 | HHLR ADVISORS, LTD. | Kiniksa Pharmaceuticals, Ltd. | 3,879,426 | 9.9% | EDGAR |
| SC 13G/A | 2024-02-14 | Fairmount Funds Management LLC | Kiniksa Pharmaceuticals, Ltd. | 2,883,221 | 8.1% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Kiniksa Pharmaceuticals, Ltd. | 2,965,299 | 8.4% | EDGAR |
| SC 13G | 2024-02-12 | Rubric Capital Management LP | Kiniksa Pharmaceuticals, Ltd. | 2,907,501 | 8.2% | EDGAR |
| SC 13G | 2024-01-25 | BlackRock Inc. | Kiniksa Pharmaceuticals, Ltd. | 3,180,588 | 9.0% | EDGAR |
| SC 13G/A | 2023-08-18 | HHLR ADVISORS, LTD. | Kiniksa Pharmaceuticals, Ltd. | 3,541,301 | 9.9% | EDGAR |
| SC 13G | 2023-08-10 | Fairmount Funds Management LLC | Kiniksa Pharmaceuticals, Ltd. | 2,143,052 | 6.1% | EDGAR |
| SC 13G/A | 2023-03-08 | BlackRock Inc. | Kiniksa Pharmaceuticals, Ltd. | 3,427,741 | 4.9% | EDGAR |
| SC 13G/A | 2023-02-14 | HHLR ADVISORS, LTD. | Kiniksa Pharmaceuticals, Ltd. | 2,623,924 | 7.6% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Kiniksa Pharmaceuticals, Ltd. | 3,226,891 | 9.3% | EDGAR |
| SC 13G | 2023-02-03 | PICTET ASSET MANAGEMENT SA | Kiniksa Pharmaceuticals, Ltd. | 1,234,193 | 3.6% | EDGAR |
| SC 13G/A | 2023-02-01 | BlackRock Inc. | Kiniksa Pharmaceuticals, Ltd. | 3,581,679 | 5.2% | EDGAR |
| SC 13G | 2022-09-08 | BlackRock Inc. | Kiniksa Pharmaceuticals, Ltd. | 3,565,982 | 5.1% | EDGAR |
| SC 13G/A | 2022-02-14 | AMERIPRISE FINANCIAL INC | Kiniksa Pharmaceuticals, Ltd. | 285 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-10 | VANGUARD GROUP INC | Kiniksa Pharmaceuticals, Ltd. | 2,890,708 | 8.5% | EDGAR |
| SC 13G | 2022-02-10 | PICTET ASSET MANAGEMENT SA | Kiniksa Pharmaceuticals, Ltd. | 3,548,649 | 5.2% | EDGAR |
| SC 13G/A | 2022-01-27 | BlackRock Inc. | Kiniksa Pharmaceuticals, Ltd. | 3,483,852 | 10.3% | EDGAR |
| SC 13G/A | 2022-01-26 | BlackRock Inc. | Kiniksa Pharmaceuticals, Ltd. | 3,483,852 | 10.3% | EDGAR |
| SC 13G | 2021-11-24 | BlackRock Inc. | Kiniksa Pharmaceuticals, Ltd. | 3,517,889 | 10.4% | EDGAR |